<SEC-DOCUMENT>0001193125-17-311829.txt : 20171017
<SEC-HEADER>0001193125-17-311829.hdr.sgml : 20171017
<ACCEPTANCE-DATETIME>20171017162705
ACCESSION NUMBER:		0001193125-17-311829
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171017
FILED AS OF DATE:		20171017
DATE AS OF CHANGE:		20171017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		171140948

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d472909d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October 17, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED
LTD </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 17, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRIMA BIOMED LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d472909dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g472909g31c79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17&nbsp;October 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>IMP321 NEW DATA ACCEPTED
FOR PRESENTATION AT THE SOCIETY FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;) announces that new data investigating the use of eftilagimod alpha
(IMP321), the Company&#146;s lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either no response or a suboptimal response to pembrolizumab, will be presented in a poster
presentation for the first time at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pushing the accelerator and releasing the
break: testing the soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma. </B>Poster Number P259 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authors</B>: Victoria Atkinson, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Adnan Khattak, Christian Mueller, Tina Dunkelmann, Chrystelle Brignone,
Frederic Triebel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SITC 2017 Annual Meeting is being held on November <FONT STYLE="white-space:nowrap">10-12,</FONT> 2017 at the Gaylord National
Hotel&nbsp;&amp; Convention Center in National Harbor, Maryland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s
current lead product is IMP321, based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble
<FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products
including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima&#146;s pharmaceutical partners. Prima is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune
disease. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information
please visit <U>www.primabiomed.com.au.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT STYLE="white-space:nowrap">378-2933;</FONT> <U>mbeck@troutgroup.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g472909g31c79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472909g31c79.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!3U/4[32+"6]O9EB@B&69C3 P
M?#.N7WBAO[42(VVE9*PHP^>7_:/H* -R_P!7L-+3=>720CMN/)J)3C#<WHT*
ME9V@KF3%XZ\/32^6M^H/JP(%9*O#N=DLKQ45=Q+^H2W%UIHN-(N$,J_,O=7'
MI6R:W1YTHRB[,S_"_C&S\1>;;$?9]1MSMGMG/S*?ZBJ).EH *0!3 *0!0 4
M% !0 4 % !0 4 % !0 4 %, I % !0 4 % !0 4 % !3 *0!0 4P"D 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MCUH XKX8_$&Y\;F_2\@BA>W(*"/N#2L D?Q(,WQ2/A>*.(VBC:9<_-OQR*+
M7?B;XTO?!6CVUY9013/++L(DZ8I@<9:?$GXA7UI'<VWAB.2&0;E90<$4 =WH
MOB'6YO!%WJ^L:>MI?PAR(><8'2@#S?2_B_XTUHS?V;H$%R(?O[ 3B@#2T;XY
M/%J'V+Q-I#6+9P73/R_4&@#V"TNX+ZTBNK:020RJ&5AW%(">@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\/V4QM&?KMYD/OZ"@#V/X>>&F\*^$+73Y1BX.9)?9CUI =50 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M'Z,*=TR>62'A@>AS039H=0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!!>1/+931QG#LA /OBF!X)\*?!\=QX]U:758]TVG,2J,/XB>M 'H7Q=\/6>J
M^";NZDC07-FOF1R8Y'M0!%\%K.XL_ $'VA&3S)&= W]TT >BT@"@ I@% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\"%.Z)<9+H.#H>C _0T]";-#@0>], I; % !FF M( H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#*?1(%U@:K; 0W17
M9(5'$B^] #M8T:+6[86EV<VA(+QCC?CL?:F!?AACMX4BA0)&@PJJ, "D!)0
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M<R_\!-0Z<ET.B.(I2V9 8)4^]$X^JFHY6C3GB]F-P0>1BE8JPX4">@HH$.%
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M3]7-2Y-]354H1VBBNTC-RSD_4TKEJ*&4BK(*$A!0,*>@!0 AI ?2U>X?G 4
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M T':@!*!A0 4 A#TH&)0 E !0 4 % !0 TT ?2]>X?G 4 % !0 4 % !0 4
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M;-;FBE%[,3!'8T .![4"%SS0 N: %H * $S0 A- "$XH ;FD-#:0T-- QAI
M)F@H:3Q0"&9H&(:"AII -I A#0,8:"AM AI-(I#3TH&-- "=: &T#$ZT#$-
M##UH&)0-#30,3I0 G2@8V@!*!H::!C30 E PSB@!M QIH&&* $H&A* "@!*
M$- "4#0E PH * "@$(>E Q* $H * "@ H 0]* $H ^EZ]P_. H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * $Q0 M !0 E !B@ Q0 ;1Z4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M;0%PHL.XE !0 4""@8AZ4 )0!]+U[A^<!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 E !0 8H 6F F*!"8]J!["&-#U13^%(=V,-M >
ML$9_X"*5D/FDNHQK"S<8:UA/_ !2Y8]BE5FNK*[Z%I<GWK"$_P# !2Y(]BE7
MJK[3*[^%=$?[VG0_E2=*#Z&BQ==;2(F\':$W_+@@^E2Z,'T+6/Q"^T0MX&T%
MO^7/'T:CV$.Q:S+$K[1 _P /=";I"Z_1JGZO3-(YKB%U*TGPUT=_NO,GXU/U
M6!HLXKKL5)/A=9$_N[R5?J*3PD>C-%G57JD5W^%:?P:BP^J4OJB[EK.I=8D+
M?"N0#Y=1'XI4_57W-5G:ZQ(F^%MY_#?1GZJ:7U27<K^VX?RD#_"_5!]RZ@/Y
MBI>$D6LZI=4RM)\--=3[I@?_ ('BI>%FC99SA_,JR?#_ ,0Q]+5&_P!UQ2^K
M5#19MA7U?W%9_!7B%.NG.?H0:7L*G8I9GA7U(&\)Z\O73)ORJ71FNAHL?AWM
M(B;PWK*?>TZ<?\!I>RGV+6,H/[2(6T35$^]83C_@!H]G-="EBJ+VDB)]-OD'
MS6DP_P" &IY6NAHJU-[,A:VG3[T+CZJ:5F7SQ[GTE7MGYT% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % #3Q1L N!Z4 -,49ZHI_"@KF:ZD;6
/=L_WH(S]5%%D/GDNI__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
